glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 Receptor Agonists as Treatments

Peleg et al., 2016

Anticancer activity Effects on carcinogen metabolism Inhibition of metabolic activation of carcinogens Some chemical carcinogens do not become active carcinogens until they have been metabolized by Phase I biotransformation enzymes, such as those belonging to the cytochrome P450 (CYP) family

Despite increased mucosal inflammation in BSO treated animals, intestinal permeability was not aggravated

developed MRA to infer causal signaling network topologies from perturbation data, revealing that resistance often arises from network architecture and kinase dimerization rather than individual feedback loops

Rhodes, S